Close menu




May 19th, 2022 | 13:31 CEST

Booster for the BioNTech share: BASF and Defense Metals with momentum?

  • RareEarths
  • Biotechnology
Photo credits: pixabay.com

The swing market continues to keep investors on their toes. On Tuesday, encouraging economic data and the prospect of an imminent end to the lockdowns in China ensured a good mood and significantly rising prices. The speech by Fed Chairman Powell could not change this. Only one day later, the euphoria has already faded, and the statements of the central bank chief are being interpreted negatively. Powell had reiterated the Fed's determination to fight inflation. Therefore, operational impulses are needed for shares to rise again. BioNTech's stock got a small boost from the FDA's approval of its Corona vaccine as a booster shot for ages 5-11. But analysts are waiting for more. At Defense Metals, investors hope for more from today's CEO presentation after solid drilling results. At BASF, several analysts are reducing price targets at once and see possible additional costs in the billions.

time to read: 3 minutes | Author: Fabian Lorenz
ISIN: BIONTECH SE SPON. ADRS 1 | US09075V1026 , BASF SE NA O.N. | DE000BASF111 , DEFENSE METALS CORP. | CA2446331035

Table of contents:


    Defense Metals: Strong drill results not enough?

    Today, there could be new momentum for the exciting rare earth explorer, Defense Metals. CEO Dr Luisa Moreno will speak at 3:20 pm at the IFF virtual investor conference. Interested investors can register for free here until shortly before the start of the presentation. Defense Metals owns Wicheeda, a huge rare earth deposit in Canada. It covers around 2,000 hectares and already has rare earth mineral resources of 4.9 million tons. Another 12 million tons are believed to still be in the ground. Earlier this year, Defense Metals conducted a 29-hole, 5,349m resource expansion and diamond drilling program at the Wicheeda property. Positive drill results have been coming in regularly since early February - although this has not allowed the stock to decouple from the weak overall market. The latest success story came at the end of April. A total grade of 3.09% was proven over a distance of 251m. A week earlier, Defense Metals had already reported a 3.81% grade rare earth oxide enrichment over a length of 117m. According to the experts at researchanalyst.com, the Wicheeda project should be in production in about five years and, as things stand today, could become one of North America's most important producers. A detailed analysis can be found here.

    By way of background, rare earths are often overlooked when discussing commodity dependence. And wrongly so. Rare earths are present in almost all technologies. Not only in smartphones and electric cars but also in modern military technology. The problem from a strategic point of view: China dominates the world market. Alternatives are hardly available. Defense Metals is working to change that. The Canadian explorer could offer around 10% of current global production in the future. From the point of view of the experts at researchanalyst.com, the Canadians should be considered an attractive takeover candidate by larger companies such as Lynas or MP Materials.

    BioNTech: Share with its first booster

    BioNTech's stock has held up relatively well in the sell-off of recent weeks, especially compared to vaccine competitor Valneva. However, for the share of the Wiesbaden-based biotech high-flyer to sustainably move forward again, new impulses are needed. Goldman Sachs also shares this opinion. Thanks to strong sales of the Corona vaccine, BioNTech generated more revenue in the first quarter than analysts had expected. In the coming weeks, the focus should now turn to trial data on the pediatric vaccine - which the FDA approved yesterday - and the Omicron-specific vaccine, the experts said. They leave the rating at "Neutral". However, the price target of USD 255 is significantly above the current level of USD 157. BioNTech has also exceeded the estimates of JPMorgan. The analysts have a price target of USD 183. Even if the Corona vaccine should lose importance, the Company is well-positioned in oncology. In the second half of the year, things should get exciting at BioNTech. Numerous study updates are expected, for example, on the active substance against skin cancer and on the mRNA based cancer vaccine. There should also be news on an mRNA vaccine against influenza. Should the data turn out to be positive, a real booster for the share can be expected.

    BASF: Analysts reduce price targets and see costs in the billions

    There is currently no positive impetus in sight for BASF. High energy prices and fears of a recession are weighing too heavily. And then there is the possible gas cut-off - whether by Germany or Russia turning off the tap. It would have a massive impact on BASF's production in Germany. Analysts are accordingly cautious. Société Générale continues to rate the chemical group as "Hold", with the price target reduced from EUR 59 to EUR 50. Baader Bank left its rating at "Add" but lowered its price target for BASF shares from EUR 60 to EUR 53. A German embargo on Russian oil and gas would mean a cost explosion of up to EUR 7.9 billion for the DAX-listed group. The probability of an actual oil embargo is currently increasing. This risk is lower for Russian gas, he said. Other groups such as Wacker Chemie, Covestro, K+S, Evonik and Lanxess would also be affected. BASF shares are currently trading at around EUR 50.


    Investors currently need strong nerves. BioNTech is holding up well, but it needs positive study results. Defense Metals regularly delivers positive drill results, but it needs more for the knot to finally burst. At BASF, investors and analysts are cautious.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author



    Related comments:

    Commented by Fabian Lorenz on June 23rd, 2022 | 11:35 CEST

    Takeover fantasy: +50% in Valneva shares, and what are BioNTech and Defence Therapeutics doing?

    • Biotechnology
    • Pharma

    Tension is rising in the biotech sector as the takeover merry-go-round spins faster and has now hit Valneva. Pfizer's entry caused the stock to explode 50% in three trading days. Earlier, Pfizer had announced it would acquire migraine specialist Biohaven for USD 11.6 billion. Other pharmaceutical giants are also active: Halozyme wants to swallow Antares Pharma, a specialist in urology and endocrinology, for USD 960 million. The acquisition of Sierra Oncology is costing GlaxoSmithKline around USD 1.9 billion. Like Valneva, Defence Therapeutics is about to start important trials and could attract a major partner. A takeover of BioNTech is unlikely, but the flagship German biotech should also benefit from improved sentiment in the industry. The coming week should be operationally exciting for shareholders.

    Read

    Commented by Nico Popp on June 22nd, 2022 | 13:01 CEST

    Crisis investments? Pharmaceutical stocks in check: Bayer, XPhyto, Pfizer

    • Biotechnology
    • Pharma

    Many investors want solid foundations for their portfolios when the market is in turmoil. Pharmaceutical stocks have always been considered largely detached from the overall market - after all, our health is not subject to market cycles. We explain whether this assumption is correct and how investors can now invest in stocks from the sector, using three shares as examples.

    Read

    Commented by Nico Popp on June 22nd, 2022 | 12:32 CEST

    Market-independent returns? This is how it's done! Valneva, NervGen, BioNTech

    • Biotechnology

    When the stock market is in high gear, it is time for cool heads. Even if many managers are suspected of only having an eye on the next few quarters, there are still some decisions with far-reaching consequences, especially in the case of takeovers and mergers. Most recently, Pfizer acquired a stake in the vaccine manufacturer Valneva. The share price performance to date did not suggest such a step. Here is why the decision could still pay off for shareholders and what signal effect the deal will have.

    Read